These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4882472)

  • 41. Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract.
    Martino S; Samal B; Al-Sarraf M
    Cancer Treat Rep; 1980 Jan; 64(1):161-3. PubMed ID: 7379051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ambulatory chemotherapy of hematosarcoma].
    Finogenova IA; Abdylbaev RA
    Vopr Onkol; 1984; 30(3):77-81. PubMed ID: 6369777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nursing management--cancer chemotherapy.
    Lane CG
    J Nurs Care; 1980 Oct; 13(10):7-11. PubMed ID: 6903601
    [No Abstract]   [Full Text] [Related]  

  • 44. [Effects of single administration of tetrahydropyranyladriamycin (THP) in lymphoid malignancy].
    Takagi T; Oguro M; Iwabuchi K
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1450-6. PubMed ID: 6588924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
    Mochizuki F; Fujii M; Kasakura Y; Yamagata M; Kochi M; Wakabayashi K; Kanamori N; Takayama T
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):493-6. PubMed ID: 12242513
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of dibromodulcitol (NSC-104800).
    Andrews NC; Weiss AJ; Wilson W; Nealon T
    Cancer Chemother Rep; 1974; 58(5 Pt 1):653-60. PubMed ID: 4426045
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
    Luce JK; Bodey GP
    Cancer Chemother Rep; 1970 Apr; 54(2):131-4. PubMed ID: 4946003
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase II clinical trial of VP-16-213 in ovarian cancer.
    Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
    Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
    [No Abstract]   [Full Text] [Related]  

  • 52. Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.
    Cascino TL; Veeder MH; Buckner JC; O'Fallon JR; Wiesenfeld M; Levitt R; Goldberg RM; Kuross SA; Morton RF; Scheithauer BW
    J Neurooncol; 1996 Dec; 30(3):243-6. PubMed ID: 8943099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in man.
    Bounous G; Gentile JM; Hugon J
    Can J Surg; 1971 Sep; 14(5):312-24. PubMed ID: 4107102
    [No Abstract]   [Full Text] [Related]  

  • 54. Phase I study of ICRF-187 using a daily for 3 days schedule.
    Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
    Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unexpected toxicity in patients treated with iphosphamide.
    Van Dyk JJ; Falkson HC; Van der Merwe AM; Falkson G
    Cancer Res; 1972 May; 32(5):921-4. PubMed ID: 4552918
    [No Abstract]   [Full Text] [Related]  

  • 56. [Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0].
    Kaba H; Fukuda H; Yamamoto S; Ohashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1187-92. PubMed ID: 15332541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).
    Creasey WA; Capizzi RL; DeConti RC
    Cancer Chemother Rep; 1970 Jun; 54(3):191-4. PubMed ID: 4946005
    [No Abstract]   [Full Text] [Related]  

  • 59. [Non-hematologic adverse effects of cytostatic drugs].
    Singer Z; Kozaczka A; Wilk J; Janas J
    Pol Tyg Lek; 1984 Nov; 39(47):1535-41. PubMed ID: 6240028
    [No Abstract]   [Full Text] [Related]  

  • 60. Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
    Ellerby RA; Davis HL; Ansfield FJ; Ramirez G
    Cancer; 1974 Oct; 34(4):1005-10. PubMed ID: 4607883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.